Becton, Dickinson and Company (BDX): Price and Financial Metrics
Becton, Dickinson and Company (BDX)
Today's Latest Price: $246.93 USD
Updated May 29 4:32pm
Add BDX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BDX Stock Summary
- Becton Dickinson & Co's market capitalization of $65,633,995,287 is ahead of 97.37% of US-listed equities.
- BDX's went public 34.43 years ago, making it older than 92.87% of listed US stocks we're tracking.
- In terms of volatility of its share price, BDX is more volatile than merely 1.44% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Becton Dickinson & Co, a group of peers worth examining would be ZTS, CAT, SYK, BSX, and BKNG.
- BDX's SEC filings can be seen here. And to visit Becton Dickinson & Co's official web site, go to www.bd.com.
BDX Stock Price Chart More Charts
BDX Price/Volume Stats
| Current price | $246.93 | 52-week high | $286.72 |
| Prev. close | $241.50 | 52-week low | $197.75 |
| Day low | $239.60 | Volume | 1,925,309 |
| Day high | $247.06 | Avg. volume | 2,252,714 |
| 50-day MA | $245.55 | Dividend yield | 1.31% |
| 200-day MA | $253.83 | Market Cap | 66.96B |
Becton, Dickinson and Company (BDX) Company Bio
Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $246.93 | $160.4 | -32% |
Below please find a table outlining a discounted cash flow forecast for BDX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Becton Dickinson & Co ranked in the 38th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Becton Dickinson & Co ended up being:
- Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
- The weighted average cost of capital for the company is 7. This value is greater than only 11.93% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -33% |
| 1% | -32% |
| 2% | -32% |
| 3% | -31% |
| 4% | -30% |
| 5% | -30% |
HBIO, TARO, ITGR, USPH, and AMED can be thought of as valuation peers to BDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...